Patrick E. Sigmon

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering by Lennox International Inc. of $300…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A and Regulation S offering by Spectrum Brands of $300 million aggregate principal amount…

Davis Polk advised Exxon Mobil Corporation on the SEC-registered offering of €1.5 billion principal amount of 0.142% notes due 2024, €1 billion principal amount of 0.524% notes due 2028, €1…

Davis Polk advised Uniti Group Inc., as issuer, in connection with a new SEC-registered at-the-market offering program by Uniti under which Uniti may issue and sell shares of its common…

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Applied Materials, Inc. of $750 million aggregate principal amount of its 1.750% notes due 2030 and $750…

Davis Polk advised Comcast Corporation on its $4 billion SEC-registered debt offering of 1.950% notes due 2031, 3.750% notes due 2040 and 2.800% notes due 2051. The 3.750% notes due 2040…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $1.0 billion aggregate principal amount of its 3.875% senior notes due 2031. The notes are guaranteed by…